- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05669092
A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status
A Randomized, Controlled, Open-label, Multicenter, Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status(APRAM)
pMMR/MSS and 32 dMMR/MSI-H patientspatients were planned to be enrolled. Patients with dMMR/MSI-H will be randomly assigned to the immunotherapy arm or short-course radiotherapy sequential immunotherapy arm; pMMR/MSS patients will receive capecitabine-irinotecan based concurrent radiotherapy before being randomly assigned to the XELIRI or FOLFRINOX arm.
The rate of complete response (sustained cCR for ≥ 1 year), long-term prognosis and adverse effects will be analyzed.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Ji Zhu
- Phone Number: 13501978674
- Email: zhuji@zjcc.org.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Zhengjiang Cancer Hospital
-
Contact:
- Ji Zhu
- Phone Number: 13501978674
- Email: zhuji@zjcc.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- pathological confirmed adenocarcinoma;
- clinical stage T2-4 and/or N+,Not suitable for initial local excision to achieve radical treatment;
- the distance from anal verge less than ≤ 5cm,or surgical evaluation concludes that direct surgical anal preservation is not possible without distance metastases;
- age 18-70 years old, female and male;
- Strong desire for anal preservation and ability to be closely monitored for at least 2 years after chemoradiotherapywith good compliance;
- without distant metastases;
- ECOG Performance status 0-1;
- Detection of UGT1A1*6 and *28 gene status (for pMMR patients);
- Sufficient bone marrow reserve and physical capacity to receive consolidation chemotherapy after chemoradiotherapy (for pMMR patients);
- with good compliance;
- signed the inform consen.
Exclusion Criteria:
- pregnant or breastfeeding women;
- Persons with a history of uncontrolled epilepsy, central nervous system disorders, or psychiatric disorders whose clinical severity, as judged by the investigator, may prevent the signing of informed consent or affect the patient's compliance with oral medications;
- Difficult to achieve complete remission at the available level of evidence, such as: tumor largest diameter >10 cm; largest diameter of lateral lymph nodes >2 cm; baseline CEA >= 100; biopsy pathology with an indolent cell carcinoma component; tumor of circumferential narrowing type on anal finger examination, with inclusion decided by the judgment of the evaluation team if necessary;
- Clinically significant (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmias requiring pharmacological intervention, or a history of myocardial infarction within the last 12 months;
- persons requiring immunosuppressive therapy for organ transplantation;
- Persons with severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;
- Subjects with baseline routine blood and biochemical indicators do not meet the following criteria: hemoglobin ≥ 90g/L; absolute neutrophil count (ANC) ≥ 1.5×109/L; platelets ≥ 100×109/L; ALT, AST ≤ 2.5 times the upper limit of normal; ALP ≤ 2.5 times the upper limit of normal; serum total bilirubin < 1.5 times the upper limit of normal; serum creatinine < 1 times the upper limit of normal limit; serum albumin ≥30g/L;
- Known to have dihydropyrimidine dehydrogenase (DPD) deficiency;
- allergic to any investigational drug component.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARM A: dMMR/MSI-H patients
patients will receive 12 cycles of PD-1 antibody
|
3mg/Kg iv d1q2w
Other Names:
|
Experimental: ARM B: dMMR/MSI-H patients
patients will receive 5*5Gy short-course radiotherapy, followed by 12 cycles of PD-1 antibody
|
3mg/Kg iv d1q2w
Other Names:
25Gy/5fx
Other Names:
|
Experimental: ARM C: pMMR/MSS patients
patients will receive CRT followed by 6 cycles of XELIRI
|
IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
Other Names:
Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
Other Names:
|
Experimental: ARM D: pMMR/MSS patients
patients will receive CRT followed by 12 cycles of FOLFRINOX
|
IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
Other Names:
Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
complete response (CR) rate.
Time Frame: The status of cCR will be evaluated after the completion of neoadjuvant therapy.
|
cCR ≥ 1 year.
|
The status of cCR will be evaluated after the completion of neoadjuvant therapy.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse effects rate.
Time Frame: From date of randomization until the date of death from any cause, assessed up to 5 years ] Rate of chemotherapy, radiotherapy and immunotherapy related adverse events.
|
CTC 4.0 standard.
|
From date of randomization until the date of death from any cause, assessed up to 5 years ] Rate of chemotherapy, radiotherapy and immunotherapy related adverse events.
|
QoL
Time Frame: From date of randomization until the date of death from any cause, assessed up to 10 years
|
Quality of life will be evaluated using EORTC QLQ-C30 score
|
From date of randomization until the date of death from any cause, assessed up to 10 years
|
3 year local recurrence free survival rate
Time Frame: From date of randomization until the date of first documented pelvic failure, assessed up to 36 months. ]
|
Rate of 3 year local recurrence free survival
|
From date of randomization until the date of first documented pelvic failure, assessed up to 36 months. ]
|
3 year disease free survival rate
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months. ]
|
Rate of 3 year disease free survival
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months. ]
|
3 year overall survival rate
Time Frame: From date of randomization until the date of death from any cause, assessed up to 36 months.
|
Rate of 3 year overall survival
|
From date of randomization until the date of death from any cause, assessed up to 36 months.
|
Organ preservation
Time Frame: From date of randomization until the date of surgery
|
TME-free survival
|
From date of randomization until the date of surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Capecitabine
- Oxaliplatin
- Irinotecan
- Immune Checkpoint Inhibitors
Other Study ID Numbers
- CARTOnG 2201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation
-
Instituto de Cardiologia do Rio Grande do SulCompletedRadiation Injury | Exposure to Ionizing Radiation | Occupational Exposure to RadiationBrazil
-
North Texas Veterans Healthcare SystemCompletedRadiation Protection | Radiation MonitoringUnited States
-
Korea Institute of Radiological & Medical SciencesActive, not recruitingRadiation Effects | Neoplasms, Radiation-Induced | Occupational Exposure to Radiation | Leukemia, Radiation-InducedKorea, Republic of
-
National Cancer Institute (NCI)CompletedRadiation-Induced Neoplasms | Breast+Neoplasm+Radiation+Etiology | Thyroid+Neoplasm+Radiation+EtiologyUnited States
-
Affiliated Hospital to Academy of Military Medical...UnknownRadiation Injuries, ExperimentalChina
-
Pluristem Ltd.Unknown
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingChronic Radiation Injury
-
Neumedicines Inc.Department of Health and Human ServicesCompletedHematopoietic Syndrome Due to Acute Radiation SyndromeUnited States
-
McMaster UniversityNot yet recruitingOxidative Stress | Radiation Exposure | DNA Damage, Radiation Induced
-
Original BioMedicals Co. Ltd.UnknownAcute Radiation SyndromeUnited States
Clinical Trials on Toripalimab
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Urothelial CarcinomaChina
-
Henan Cancer HospitalUnknownEsophageal Squamous Cell Carcinoma
-
Sun Yat-sen UniversityThe First Affiliated Hospital of Guangzhou Medical University; Guangzhou Panyu...RecruitingStudy of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent ChemoradiotherapySmall Cell Lung Cancer Limited StageChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHead and Neck Squamous Cell CarcinomasChina
-
Shanghai Junshi Bioscience Co., Ltd.Not yet recruitingMelanoma | Breast Cancer | Lung CanceChina
-
Zhejiang Genfleet Therapeutics Co., Ltd.CompletedAdvanced Solid TumorChina, Australia
-
Fudan UniversityUnknownMelanoma Stage IIIB-IVChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, Taiwan, Georgia, United States
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Qianfoshan HospitalRecruiting